Development of Yersinia pestis F1 antigen-loaded microspheres vaccine against plague

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 813-822

  Huang, Shih Shiung ^a   Li, I Hsun ^b   Hong, Po Da ^a   Yeh, Ming Kung ^a,b,c  

^a NATIONAL TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^c Ministry of Health and Welfare   (Taiwan)

Author keywords

Immunological; PLGA; Protective responses

Indexed keywords

BACTERIAL ANTIGEN; BACTERIAL PROTEIN; BACTERIAL VACCINE; BACTERIUM ANTIBODY; CAF1 PROTEIN, YERSINIA PESTIS; CYTOKINE; DRUG CARRIER; IMMUNOGLOBULIN G; MACROGOL DERIVATIVE; MICROSPHERE; NANOPARTICLE; POLY(LACTIC-GLYCOLIC ACID)-POLY(ETHYLENEGLYCOL) COPOLYMER; POLYGLACTIN;

ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CHEMISTRY; DRUG DELIVERY SYSTEM; IMMUNOLOGY; MOUSE; NANOMEDICINE; PLAGUE; ULTRASTRUCTURE; YERSINIA PESTIS;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BACTERIAL VACCINES; CYTOKINES; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; MICROSPHERES; NANOMEDICINE; NANOPARTICLES; PLAGUE; POLYETHYLENE GLYCOLS; POLYGLACTIN 910; YERSINIA PESTIS;

EID: 84893814221     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S56260     Document Type: Article

References (48)

1. Butler T. Plague gives surprises in the first decade of the 21st century in the United States and worldwide. Am J Trop Med Hyg. 2013;89(4): 788-793.
2. Meyer KF. Effectiveness of live or killed plague vaccines in man. Bull World Health Organ. 1970;42(5):653-666.
3. Tiball RW, Williamson ED. Yersinia pestis (plague) vaccines. Expert Opin Biol Ther. 2004;4(6):965-973.
4. Feodorova VA, Motin VL. Plague vaccines: current developments and future perspectives. Emerg Microbes Infect. 2012;1(11):e36.
5. Wang X, Zhang X, Zhou D, Yang R. Live-attenuated Yersinia pestis vaccines. Expert Rev Vaccines. 2013;12(6):677-686.
6. Ali R, Naqvi RA, Kumar S, Bhat AA, Rao DN. Multiple antigen peptide containing B and T cell epitopes of F1 antigen of Yersinia pestis showed enhanced Th1 immune response in murine model. Scand J Immunol. 2013;77(5):361-371.
7. Thomas RJ, Webber D, Collinge A, et al. Different pathologies but equal levels of responsiveness to the recombinant F1 and V antigen vaccine and ciprofloxacin in a murine model of plague caused by smalland large-particle aerosols. Infect Immun. 2009;77(4):1315-1323.
8. Sabhnani L, Manocha M, Sridevi K, Shashikiran D, Rayanade R, Rao DN. Developing subunit immunogens using B and T cell epitopes and their constructs derived from the F1 antigen of Yersinia pestis using novel delivery vehicles. FEMS Immunol Med Microbiol. 2003;38(3): 215-229.
9. Williamson ED, Oyston PC. Protecting against plague: towards a nextgeneration vaccine. Clin Exp Immunol. 2013;172(1):1-8.
10. Zav'yalov V, Denesyuk A, Zav'yalova G, Korpela T. Molecular modeling of the steric structure of the envelope F1 antigen of Yersinia pestis. Immunol Lett. 1995;45(1-2):19-22.
11. Zavialov AV, Berglund J, Pudney AF, et al. Structure and biogenesis of the capsular F1 antigen from Yersinia pestis: preserved folding energy drives fiber formation. Cell. 2003;113(5):587-596.
12. Powell BS, Andrews GP, Enama JT, et al. Design and testing for a nontagged F1-V fusion protein as vaccine antigen against bubonic and pneumonic plague. Biotechnol Prog. 2005;21(5):1490-1510.
13. Eldridge JH, Staas JK, Meulbroek JA, McGhee JR, Tice TR, Gilley RM. Biodegradable microspheres as a vaccine delivery system. Mol Immunol. 1991;28(3):287-294.
14. Korsholm KS. One does not fit all: new adjuvants are needed and vaccine formulation is critical. Expert Rev Vaccines. 2011;10(1):45-48.
15. Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces. 2010;75(1): 1-18.
16. Kuo-Haller P, Cu Y, Blum J, Appleton JA, Saltzman WM. Vaccine delivery by polymeric vehicles in the mouse reproductive tract induces sustained local and systemic immunity. Mol Pharm. 2010;7(5): 1585-1595.
17. Yeh MK, Coombes AG, Chen JL, Chiang CH. Japanese encephalitis virus vaccine formulations using PLA lamellar and PLG microparticles. J Microencapsul. 2002;19(5):671-682.
18. Wischke C, Schwendeman SP. Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles. Int J Pharm. 2008;364(2): 298-327.
19. Yeht MK, Chen JL, Chiang CH. Vibrio cholerae-loaded poly(DL lactide co-glycolide) microparticles. J Microencapsul. 2002;19(2): 203-212.
20. Yeh MK, Davis SS, Coombes AG. Improving protein delivery from microparticles using blends of poly(DL lactide co-glycolide) and poly(ethylene oxide)-poly(propylene oxide) copolymers. Pharm Res. 1996;13(11):1693-1698.
21. Mundargi RC, Babu VR, Rangaswamy V, Patel P, Aminabhavi TM. Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives. J Control Release. 2008;125(3):193-209.
22. Rao DA, Forrest ML, Alani AW, Kwon GS, Robinson JR. Biodegradable PLGA based nanoparticles for sustained regional lymphatic drug delivery. J Pharm Sci. 2010;99(4):2018-2031.
23. Elkharraz K, Ahmed AR, Dashevsky A, Bodmeier R. Encapsulation of water-soluble drugs by an o/o/o-solvent extraction microencapsulation method. Int J Pharm. 2011;409(1-2):89-95.
24. Chen JL, Yeh MK, Chiang CH. The mechanism of surface-indented protein-loaded PLGA microparticle formation: the effects of salt (NaCl) on the solidification process. J Microencapsul. 2004;21(8): 877-888.
25. Fredenberg S, Wahlgren M, Reslow M, Axelsson A. The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems-a review. Int J Pharm. 2011;415(1-2):34-52.
26. Freitas S, Merkle HP, Gander B. Microencapsulation by solvent extraction/evaporation: reviewing the state of the art of microsphere preparation process technology. J Control Release. 2005;102(2):313-332.
27. Heegaard PM, Dedieu L, Johnson N, et al. Adjuvants and delivery systems in veterinary vaccinology: current state and future developments. Arch Virol. 2011;156(2):183-202.
28. Yeh M, Chiang C. Inactive Vibrio cholerae whole-cell vaccine-loaded biodegradable microparticles: in vitro release and oral vaccination. J Microencapsul. 2004;21(1):91-106.
29. Coombes AG, Yeh MK, Lavelle EC, Davis SS. The control of protein release from poly(DL-lactide co-glycolide) microparticles by variation of the external aqueous phase surfactant in the water-in oil-in water method. J Control Release. 1998;52(3):311-320.
30. Huang SS, Li IH, Hong PD, Yeh MK. Evaluation of protective efficacy using a nonstructural protein NS1 in DNA vaccine-loaded microspheres against dengue 2 virus. Int J Nanomedicine. 2013;8:3161-3169.
31. Wang Y, Hao J, Li Y, et al. Poly(caprolactone)-modified Pluronic P105 micelles for reversal of paclitaxcel-resistance in SKOV-3 tumors. Biomaterials. 2012;33(18):4741-4751.
32. Wu SF, Liao CL, Lin YL, et al. Evaluation of protective efficacy and immune mechanisms of using a non-structural protein NS1 in DNA vaccine against dengue 2 virus in mice. Vaccine. 2003;21(25-26): 3919-3929.
33. Yamanaka H, Hoyt T, Yang X, et al. A nasal interleukin-12 DNA vaccine coexpressing Yersinia pestis F1-V fusion protein confers protection against pneumonic plague. Infect Immun. 2008;76(10): 4564-4573.
34. Reddin KM, Easterbrook TJ, Eley SM, et al. Comparison of the immunological and protective responses elicited by microencapsulated formulations of the F1 antigen from Yersinia pestis. Vaccine. 1998;16(8): 761-767.
35. Florence AT, Hillery AM, Hussain N, Jani PU. Factors affecting the oral uptake and translocation of polystyrene nanoparticles: histological and analytical evidence. J Drug Target. 1995;3(1):65-70.
36. Oyewumi MO, Kumar A, Cui Z. Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert Rev Vaccines. 2010;9(9):1095-1107.
37. Rosli R, Nograles N, Hanafi A, Nor Shamsudin M, Abdullah S. Mucosal genetic immunization through microsphere-based oral carriers. Hum Vaccin Immunother. 2013;9(10).
38. Thomas C, Gupta V, Ahsan F. Influence of surface charge of PLGA particles of recombinant hepatitis B surface antigen in enhancing systemic and mucosal immune responses. Int J Pharm. 2009;379(1): 41-50.
39. He J, Feng M, Zhou X, et al. Stabilization and encapsulation of recombinant human erythropoietin into PLGA microspheres using human serum albumin as a stabilizer. Int J Pharm. 2011;416(1):69-76.
40. Heo S, Lee M, Lee S, Sah H. Investigation on structural integrity of PLGA during ammonolysis-based microencapsulation process. Int J Pharm. 2011;419(1-2):60-70.
41. Li M, Rouaud O, Poncelet D. Microencapsulation by solvent evaporation: state of the art for process engineering approaches. Int J Pharm. 2008;363(1-2):26-39.
42. Li Z, Zhang L, Sun W, Ding Q, Hou Y, Xu Y. Archaeosomes with encapsulated antigens for oral vaccine delivery. Vaccine. 2011;29(32): 5260-5266.
43. Mata E, Igartua M, Patarroyo ME, Pedraz JL, Hernández RM. Enhancing immunogenicity to PLGA microparticulate systems by incorporation of alginate and RGD-modified alginate. Eur J Pharm Sci. 2011;44(1-2): 32-40.
44. Kuroda E, Coban C, Ishii KJ. Particulate adjuvant and innate immunity: past achievements, present findings, and future prospects. Int Rev Immunol. 2013;32(2):209-220.
45. Parent MA, Berggren KN, Kummer LW, et al. Cell-mediated protection against pulmonary Yersinia pestis infection. Infect Immun. 2005;73(11): 7304-7310.
46. Shen H, Ackerman AL, Cody V, et al. Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles. Immunology. 2006;117(1): 78-88.
47. Schliehe C, Redaelli C, Engelhardt S, et al. CD8-dendritic cells and macrophages cross-present poly(D,L-lactate-co-glycolate) acid microsphere-encapsulated antigen in vivo. J Immunol. 2011;187(5): 2112-2121.
48. Nayak B, Ray AR, Panda AK, Ray P. Improved immunogenicity of biodegradable polymer particles entrapped rotavirus vaccine. J Biomater Appl. 2011;25(5):469-496.